MediciNova, Inc. (4875.T)
Tokyo · JPY · Healthcare · Biotechnology
¥223 (-0.45%) as of
Key statistics
- Market cap
- 10.98B
- Forward P/E
- -2.77
- EPS (TTM)
- -32.43
- Dividend yield
- 0.00%
- 52-week range
- 174.00 – 510.00
- Beta
- 0.61
- Revenue (TTM)
- 920.48k
- Profit margin
- 0.00%
- Volume
- 28.70k
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- La Jolla, CA, United States
- Employees
- 6
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.